Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative
1998

Reversal of Multidrug Resistance by XR9051

publication Evidence: high

Author Information

Author(s): IL Dale, W Tuffley, R Callaghan, JA Holmes, K Martin, M Luscombe, P Mistry, H Ryder, AJ Stewart, P Chariton, PR Twentyman, P Bevan

Primary Institution: Xenova Ltd.

Hypothesis

Can XR9051 effectively reverse P-glycoprotein-mediated multidrug resistance in cancer cells?

Conclusion

XR9051 is a potent modulator that can reverse multidrug resistance in various cancer cell lines by interacting directly with P-glycoprotein.

Supporting Evidence

  • XR9051 was able to fully sensitize resistant cells to cytotoxic drugs.
  • XR9051 was consistently more potent than cyclosporin A and verapamil.
  • XR9051 inhibited the efflux of daunorubicin from preloaded cells.
  • XR9051 remained active for several hours after removal from the medium.
  • XR9051 showed no effect on non-MDR cytotoxics like methotrexate.

Takeaway

XR9051 is a new drug that helps cancer treatments work better by stopping cancer cells from pushing the medicine out.

Methodology

The study used various human and murine drug-resistant cell lines to test the effectiveness of XR9051 in reversing drug resistance.

Limitations

The study primarily focused on in vitro results, which may not fully translate to in vivo effectiveness.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication